Advanced Therapies for Blood Purification Market to Reach $7.37B by 2033

Driven by rising chronic disease prevalence and technological innovations in blood filtration and detoxification

Feb. 3, 2026 at 6:07am

Got story updates? Submit your updates here. ›

The global advanced therapies for blood purification market is projected to grow from $3.53 billion in 2023 to $7.37 billion by 2033, at a robust CAGR of 7.8%. The increasing prevalence of chronic kidney diseases, sepsis, and autoimmune disorders, along with the rising adoption of novel blood purification techniques like hemoperfusion, plasma exchange, and extracorporeal blood detoxification, are driving market expansion. Technological advancements in biocompatible membranes, nanofiber filters, and adsorption columns, combined with growing awareness of blood purification benefits in critical care and transplant therapies, are further fueling growth.

Why it matters

The advanced blood purification market is being propelled by the rising global burden of chronic diseases, particularly kidney disease, sepsis, and autoimmune disorders. Innovations in filtration, adsorption, and monitoring technologies are improving patient outcomes and reducing hospital stays. As personalized medicine and minimally invasive therapies gain traction, the demand for advanced blood purification modalities is expected to accelerate, transforming critical and chronic disease management.

The details

The market is segmented by therapy type, with hemoperfusion and hemoadsorption accounting for the largest share, followed by plasma exchange, hemodialysis, and immunoadsorption. By end-user, hospitals and dialysis centers dominate, but ambulatory care clinics and research institutes are also key contributors. Geographically, North America leads the market, followed by Europe and the fast-growing Asia-Pacific region.

  • The global advanced therapies for blood purification market was valued at $3.53 billion in 2023.
  • The market is projected to reach $7.37 billion by 2033, growing at a CAGR of 7.8% from 2025 to 2033.

The players

Baxter International Inc.

A leading medical device manufacturer that has launched new cytokine adsorption cartridges and expanded its high cut-off dialysis membrane production capacity.

Fresenius Medical Care AG & Co. KGaA

A major provider of dialysis products and services that has expanded its high cut-off dialysis membrane production capacity in Europe.

Cytosorbents Corporation

A biotech firm that received FDA approval for its hemoadsorption device targeting septic shock patients.

Terumo Corporation

A medical device company that partnered with leading US hospitals to pilot immunoadsorption therapy for autoimmune diseases.

Asahi Kasei Medical Co., Ltd.

A Japanese company that introduced next-generation plasma exchange systems with improved biocompatibility and filtration rates.

Got photos? Submit your photos here. ›

What’s next

As personalized medicine and minimally invasive therapies gain traction, the demand for advanced blood purification modalities is expected to accelerate, transforming critical and chronic disease management. Industry leaders are focused on expanding their product portfolios, forging strategic partnerships, and exploring emerging markets to capitalize on this growing opportunity.

The takeaway

The advanced blood purification market is poised for significant growth, driven by the rising global burden of chronic diseases and the increasing adoption of innovative filtration, adsorption, and monitoring technologies. This market transformation presents opportunities for medical device manufacturers, biotech firms, and specialized startups to develop cutting-edge solutions that improve patient outcomes and reduce healthcare costs.